Anavex Life Sciences Business Update
Anavex Life Sciences announced the completion of clinical conduct for two pharmacology studies (ADME and DDI) for blarcamesine (ANAVEX 2-73) in healthy volunteers. The company also reported FDA clearance of its IND application for Fragile X syndrome and an upcoming November meeting with the FDA regarding its Phase 3 Rett syndrome study.